Overview

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of a quadruple regimen (VX-222, telaprevir, pegylated interferon, and ribavirin)in subjects with hepatitis C with cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin